Q1 2025 · 13F-HR
BIOS Capital Management, LPholdings as filed
Filed 2025-05-14 · accession 0001104659-25-048606
$79.2M
Reported value
6
Positions
2025-03-31
Period end
The Brief · BIOS Capital Management, LP · Q1 2025
AI · grounded in 13F
BIOS Capital Management, LP reported no changes to its 13F holdings for 2025-03-31 relative to 2024-12-31.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 005083100 | ACTU | ACTUATE THERAPEUTICS INC | $67.0M | 84.6% | 9,893,651 | Common | SHARED |
| 51654W101 | LTRN | LANTERN PHARMA INC | $4.3M | 5.40% | 1,207,709 | Common | SHARED |
| 00887A204 | RNTX | REIN THERAPEUTICS INC | $3.0M | 3.78% | 1,690,751 | Common | SHARED |
| 19243B102 | CGTX | COGNITION THERAPEUTICS INC | $2.5M | 3.19% | 6,000,000 | Common | SHARED |
| 45674E109 | INABEUR | IN8BIO INC | $1.4M | 1.80% | 8,600,001 | Common | SHARED |
| 67577R102 | IRD | OPUS GENETICS INC | $977,135 | 1.23% | 995,249 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.